GSWM
SKYE icon

Golden State Wealth Management’s Skye Bioscience SKYE Stock Holding History

Golden State Wealth Management’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2
Closed -$6 – 1648
2024
Q4 		$6 Buy
+2
New +$8 ﹤0.01% 1511

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Golden State Wealth Management's SKYE Position: Q1 2025 in Review

Golden State Wealth Management sold out of Skye Bioscience (SKYE) in Q1 2025, closing a stake of 2 shares — an estimated $6 sold.

Golden State Wealth Management first reported a position in SKYE in Q4 2024 and held it in 1 quarter. The position peaked at $6 in Q4 2024. 75 funds tracked by Wall St. Rank hold SKYE as of Q1 2025.

  • Golden State Wealth Management reported no remaining Skye Bioscience position as of Q1 2025 after selling out during the quarter.
  • Golden State Wealth Management sold 2 Skye Bioscience shares in Q1 2025, an estimated $6.
  • Golden State Wealth Management first reported a position in Skye Bioscience in Q4 2024 and held it in 1 quarter.
  • Golden State Wealth Management's Skye Bioscience position peaked at $6 in Q4 2024.
  • 75 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2025.

Based on Golden State Wealth Management's 13F filing for Q1 2025, filed 23 Apr 2025.